{"id":290,"date":"2024-10-07T10:12:39","date_gmt":"2024-10-07T10:12:39","guid":{"rendered":"https:\/\/dev.therapeuticsolutionsint.com\/?page_id=290"},"modified":"2024-10-25T11:05:37","modified_gmt":"2024-10-25T11:05:37","slug":"leukemia-stemvacs-h","status":"publish","type":"page","link":"https:\/\/stemvacs.therapeuticsolutionsint.com\/index.php\/leukemia-stemvacs-h\/","title":{"rendered":"Leukemia &#8211; StemVacs-H"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Header&#8221; _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;gcid-3cfc8c0c-5557-4a5d-9dab-24e78d615311&#8243; custom_padding=&#8221;61px|||||&#8221; collapsed=&#8221;on&#8221; global_colors_info=&#8221;{%22gcid-3cfc8c0c-5557-4a5d-9dab-24e78d615311%22:%91%22background_color%22%93}&#8221;][et_pb_row _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;0px||0px|||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;-47px|||||&#8221; custom_padding=&#8221;2px||0px|||&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>The following list of <strong>cancer immunotherapies<\/strong> are available for licensing under <a href=\"https:\/\/patents.justia.com\/patent\/20220235325\" target=\"_blank\" rel=\"noopener\">U.S. Patent Publication No.: <\/a><span><a href=\"https:\/\/patents.justia.com\/patent\/20220235325\" target=\"_blank\" rel=\"noopener\">20220235325<\/a>.<\/span><\/p>\n<p><strong>Stimulation of Dendritic Cell Activity by Homotaurine and Analogues Thereof<\/strong><\/p>\n<div class=\"horizontal layout style-scope patent-result\">\n<div class=\"flex-3 style-scope patent-result\" marginright=\"\">\n<section id=\"abstract\" class=\"style-scope patent-result\">\n<div class=\"flex style-scope patent-result\">Abstract<\/div>\n<div class=\"layout horizontal style-scope patent-text\">\n<section id=\"text\" class=\"flex style-scope patent-text\"><span>Disclosed are means, methods, and compositions of matter useful for enhancement of dendritic cell activity. In one embodiment the invention provides the use of GABA agonists such as homotaurine for stimulation of dendritic cell activity. In one embodiment said dendritic cell activity is enhancement of natural killer cell activity and\/or of T cell activity. In one embodiment NK cell activity is ability to induce cytotoxicity in neoplastically transformed cells, whereas T cell activity is either cytokine production for CD4 cells or cytotoxicity for CD8 cells.<\/span><\/section>\n<\/div>\n<\/section>\n<\/div>\n<\/div>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;-99px|auto||auto||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;-149px|||||&#8221; custom_padding=&#8221;40px|||||&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<html><br \/>\n<head><br \/>\n    <script src=\"https:\/\/ajax.googleapis.com\/ajax\/libs\/jquery\/1.12.4\/jquery.min.js\"><\/script><br \/>\n    <script>\n        $(function() {\n            $('.info').hide();\n            $('#countryList').on('change', function() {\n                $('.info').hide();\n                var countryCode = $('#countryList').val();\n                $('.info.' + countryCode).show();\n            });\n        });\n    <\/script><br \/>\n<\/head><br \/>\n<body><br \/>\n<select id=\"countryList\"><option value=\"\">[Select Disease]<\/option><option value=\"2\">Acute nonlymphocytic leukemia<\/option><option value=\"3\">Chronic lymphocytic leukemia<\/option><option value=\"4\">Acute granulocytic leukemia<\/option><option value=\"5\">Chronic granulocytic leukemia<\/option><option value=\"6\">Acute promyelocytic leukemia<\/option><option value=\"7\">Adult t-cell leukemia<\/option><option value=\"8\">A leukemic leukemia<\/option><option value=\"9\">A leukocythemic leukemia<\/option><option value=\"10\">Basophilic leukemia<\/option><option value=\"11\">Blast cell leukemia<\/option><option value=\"12\">Chronic myelocytic leukemia<\/option><option value=\"13\">Leukemia cutis<\/option><option value=\"14\">Embryonal leukemia<\/option><option value=\"15\">Eosinophilic leukemia<\/option><option value=\"16\">Gross&#8217; leukemia<\/option><option value=\"17\">Rieder cell leukemia<\/option><option value=\"18\">Schilling&#8217;s leukemia<\/option><option value=\"19\">Stem cell leukemia<\/option><option value=\"20\">Subleukemic leukemia<\/option><option value=\"21\">Undifferentiated cell leukemia<\/option><option value=\"22\">Hairy-cell leukemia<\/option><option value=\"23\">Hemoblastic leukemia<\/option><option value=\"24\">Hemocytoblastic leukemia<\/option><option value=\"25\">Histiocytic leukemia<\/option><option value=\"26\">Acute monocytic leukemia<\/option><option value=\"27\">Leukopenic leukemia<\/option><option value=\"28\">Lymphatic leukemia<\/option><option value=\"29\">Lymphoblastic leukemia<\/option><option value=\"30\">Lymphocytic leukemia<\/option><option value=\"31\">Lymphogenous leukemia<\/option><option value=\"32\">Lymphoid leukemia<\/option><option value=\"33\">Lymphosarcoma cell leukemia<\/option><option value=\"34\">Mast cell leukemia<\/option><option value=\"35\">Megakaryocyticleukemia<\/option><option value=\"36\">Micromyeloblastic leukemia<\/option><option value=\"37\">Monocytic leukemia<\/option><option value=\"38\">Myeloblastic leukemia<\/option><option value=\"39\">Myelocytic leukemia<\/option><option value=\"40\">Myeloid granulocytic leukemia<\/option><option value=\"41\">Myelomonocytic leukemia<\/option><option value=\"42\">Naegeli leukemia<\/option><option value=\"43\">Plasma cell leukemia<\/option><option value=\"44\">Plasmacytic leukemia<\/option><option value=\"45\">Promyelocytic leukemi<\/option><\/select><\/p>\n<div class=\"info 2\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Acute nonlymphocytic leukemia is a fast-growing cancer in which too many myeloblasts (a type of immature white blood cell) are found in the bone marrow and blood. Acute nonlymphocytic leukemia usually gets worse quickly if it is not treated. It can spread outside the blood to other parts of the body, including the lymph nodes, spleen, liver, central nervous system (brain and spinal cord), skin, gums, and testicles. Acute nonlymphocytic leukemia is most common in older adults. Also called acute myelogenous leukemia, acute myeloid leukemia, AML, and ANLL.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 3\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Chronic lymphocytic leukemia is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). CLL is a cancer of the blood and bone marrow that usually gets worse slowly.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 4\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Acute granulocytic leukemia is a cancer of the blood and bone marrow \u2014 the spongy tissue inside bones where blood cells are made.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 5\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Chronic granulocytic leukemia  typically affects older adults. It&#8217;s caused by a chromosome mutation that occurs spontaneously. Doctors aren&#8217;t sure what causes the mutation.<br \/>\n<\/table>\n<\/div>\n<\/table>\n<\/div>\n<div class=\"info 6\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Acute promyelocytic leukemia is a subtype of acute myeloid leukemia, a cancer of the white blood cells. In APL, there is an abnormal accumulation of immature granulocytes called promyelocytes.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 7\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Adult t-cell leukemia (ATL) is a highly aggressive mature T-cell neoplasm associated with human T-cell lymphotropic virus type 1 (HTLV-1) infection, which affects around 10 million people in the world.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 8\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Aleukemic leukemia is the primary extramedullary cutaneous infiltration of neoplastic leukemic cells that occasionally precede systemic leukemia diagnosis. This study aimed to investigate the clinical characteristics, management, and outcomes of ALC patients to expand our knowledge of this rare entity.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 9\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Aleukocythemic leukemia  is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). CLL is a cancer of the blood and bone marrow that usually gets worse slowly.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 10\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Basophilic leukemia  is an extremely rare type of leukemia and very little information related to the prognosis and survival of this rare variant is available.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 11\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Blast cell leukemia is abnormal immature white blood cells (called blasts) multiply uncontrollably, filling up the bone marrow, and preventing production of other cells important for survival, namely red blood cells and platelets. This leads to infections, anemia and abnormal bleeding.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 12\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Chronic myelocytic leukemia typically affects older adults. It&#8217;s caused by a chromosome mutation that occurs spontaneously. Doctors aren&#8217;t sure what causes the mutation.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 13\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Leukemia cutis  is the infiltration of neoplastic leukocytes or their precursors into the epidermis, the dermis, or the subcutis, resulting in clinically identifiable cutaneous lesions. The dermatologist is often instrumental in the diagnosis of leukemia cutis.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 14\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Embryonal leukemia are uncontrolled growths of cells in the brain. The growths involve cells that are left over from fetal development, called embryonal cells.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 15\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Eosinophilic leukemia is a blood cancer that causes an excess of eosinophils in the body.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 16\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Gross&#8217; leukemia is a cancer of the blood, characterized by the rapid growth of abnormal blood cells. This uncontrolled growth takes place in your bone marrow.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 17\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Rieder cell leukemia is an abnormal form of lymphocyte with a greatly indented nucleus, usually observed in certain examples of chronic lymphocytic leukemia.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 18\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Schilling&#8217;s leukemia  proposes that all monocytic leukemias were derived from the reticuloendothelial system<br \/>\n<\/table>\n<\/div>\n<div class=\"info 19\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Stem cell leukemia occurs most often in adults older than 55, but it is also the most common cancer in children younger than 15.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 20\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Subleukemic leukemia, also known as leukemia subleukemic and aleukemic leukemia cutis, is a rare, cancerous blood disease characterized by the presence of abnormal or atypical white blood cells in the peripheral blood while the total white blood cell count is within the normal range.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 21\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Undifferentiated cell leukemia is a rare acute leukemia of ambiguous lineage characterized by clonal proliferation of primitive hematopoietic cells, primarily in the bone marrow and blood, lacking lineage-specific markers and detectable genotypic alterations.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 22\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Hairy-cell leukemia  is an uncommon hematological malignancy characterized by an accumulation of abnormal B lymphocytes. It is usually classified as a subtype of chronic lymphocytic leukemia.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 23\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Hemoblastic leukemia  is a subtype of acute myeloid leukemia (AML).<br \/>\n<\/table>\n<\/div>\n<div class=\"info 24\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Hemocytoblastic leukemia is a group of blood cancers that usually begin in the bone marrow and produce high numbers of abnormal blood cells.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 25\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Histiocytic leukemia is an extremely rare malignant neoplasm. Tumors can occur over a wide range of ages (median age: 46 years), and is more common in males.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 26\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Acute monocytic leukemia  is a type of acute myeloid leukemia. In AML-M5 >80% of the leukemic cells are of monocytic lineage.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 27\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Leukopenic leukemia is when a person has a low white blood cell count. The most common type of leukopenia is neutropenia, which refers to low levels of neutrophils.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 28\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Lymphatic leukemia are a group of leukemias affecting circulating lymphocytes, a type of white blood cell. The lymphocytic leukemias are closely related to lymphomas of the lymphocytes, to the point that some of them are unitary disease entities that can be called by either name.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 29\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Lymphoblastic leukemia s a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). Leukemia may affect red blood cells, white blood cells, and platelets. Previous chemotherapy and exposure to radiation may increase the risk of developing ALL.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 30\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Lymphocytic leukemia  is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). CLL is a cancer of the blood and bone marrow that usually gets worse slowly.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 31\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Lymphogenous leukemia is a type of cancer of the blood and bone marrow \u2014 the spongy tissue inside bones where blood cells are made. The word &#8220;acute&#8221; in acute lymphocytic leukemia comes from the fact that the disease progresses rapidly and creates immature blood cells, rather than mature ones.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 32\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Lymphoid leukemias  are a group of leukemias affecting circulating lymphocytes, a type of white blood cell. The lymphocytic leukemias are closely related to lymphomas of the lymphocytes, to the point that some of them are unitary disease entities that can be called by either name.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 33\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Lymphosarcoma cell leukemia is an atypical, large lymphocyte with coarsely reticulated nuclear chromatin and a single prominent nucleolus. The maturity of these cells correlates with the chronicity or acuteness of the leukemic process.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 34\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Mast cell leukemia is the leukemic form of SM with at least 20% mostly immature mast cells on bone marrow aspirate.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 35\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Megakaryocyticleukemia  is a rare malignancy affecting megakaryocytes, platelet-producing cells that reside in the bone marrow.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 36\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Micromyeloblastic leukemia  is characterized by the clonal proliferation of undifferentiated myeloid precursors, known as blasts, within the bone marrow compartment.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 37\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Monocytic leukemia is a type of myeloid leukemia characterized by a dominance of monocytes in the marrow.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 38\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Myeloblastic leukemia  is a type of cancer that starts in the blood-forming cells of the bone marrow.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 39\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Myelocytic leukemia  is a cancer of the blood and bone marrow \u2014 the spongy tissue inside bones where blood cells are made.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 40\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Myeloid granulocytic leukemia  is blood cancer that starts in the blood-forming myeloid cells or stem cells in your bone marrow.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 41\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Myelomonocytic leukemia is a type of leukemia, which are cancers of the blood-forming cells of the bone marrow. In adults, blood cells are formed in the bone marrow, by a process that is known as haematopoiesis.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 42\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Naegeli leukemia, unknown factors may cause alterations in the type of cell released from the marrow.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 43\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Plasma cell leukemia is defined by the presence of 5% or more circulating plasma cells in peripheral blood smears.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 44\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Plasmacytic leukemia is a rare, yet aggressive form of multiple myeloma (MM) characterized by plasma cells circulating in the peripheral blood that can be detected on conventional peripheral blood smear examination.<br \/>\n<\/table>\n<\/div>\n<div class=\"info 45\">\n<table style=\"width:100%\">\n<table style=\"width:100%\">\n<tr>\n<th>Upfront Fee<\/th>\n<th>Annual Minimum Royalty<\/th>\n<th>Phase 1 IND<\/th>\n<th>Phase 2 IND<\/th>\n<th>Phase 3 IND<\/th>\n<th>BLA<\/th>\n<th>Royalty<\/th>\n<\/tr>\n<tr>\n<td>$50,000<\/td>\n<td>$10,000<\/td>\n<td>$100,000<\/td>\n<td>$250,000<\/td>\n<td>$500,000<\/td>\n<td>$1,000,000<\/td>\n<td>6%<\/td>\n<\/tr>\n<p>Promyelocytic leukemi is a subtype of acute myeloid leukemia, a cancer of the white blood cells. In APL, there is an abnormal accumulation of immature granulocytes called promyelocytes.<br \/>\n<\/table>\n<\/div>\n<p><\/body><br \/>\n<\/html>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The following list of cancer immunotherapies are available for licensing under U.S. Patent Publication No.: 20220235325. Stimulation of Dendritic Cell Activity by Homotaurine and Analogues Thereof Abstract Disclosed are means, methods, and compositions of matter useful for enhancement of dendritic cell activity. In one embodiment the invention provides the use of GABA agonists such as [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-290","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/stemvacs.therapeuticsolutionsint.com\/index.php\/wp-json\/wp\/v2\/pages\/290","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stemvacs.therapeuticsolutionsint.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/stemvacs.therapeuticsolutionsint.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/stemvacs.therapeuticsolutionsint.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stemvacs.therapeuticsolutionsint.com\/index.php\/wp-json\/wp\/v2\/comments?post=290"}],"version-history":[{"count":4,"href":"https:\/\/stemvacs.therapeuticsolutionsint.com\/index.php\/wp-json\/wp\/v2\/pages\/290\/revisions"}],"predecessor-version":[{"id":364,"href":"https:\/\/stemvacs.therapeuticsolutionsint.com\/index.php\/wp-json\/wp\/v2\/pages\/290\/revisions\/364"}],"wp:attachment":[{"href":"https:\/\/stemvacs.therapeuticsolutionsint.com\/index.php\/wp-json\/wp\/v2\/media?parent=290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}